AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID19 vaccine candidate, in a deal that will pay the gene and cell therapy firm 15 million pounds ($20 million) upfront and an additional 35 million pounds plus other costs by the end of 2021.
AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker’s COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm 15 million pounds ($20 million) upfront and an additional 35 million pounds plus other costs by the end of 2021.
Oxford Biomedica said in a statement that under the deal it would mass-produce the potential vaccine, AZD1222, for the novel coronavirus for a period of 18 months, which may be further extended by another 18 months into 2022 and 2023.
($1 = 0.7458 pounds)
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Comments
0 comment